Last update 28 May 2025

Anakinra (Amgen)

Overview

Basic Info

Drug Type
Interleukins
Synonyms
anakinra, Anakinra (Amgen/SOBI), Anakinra (USAN/INN)
+ [6]
Target
Action
antagonists
Mechanism
IL1R1 antagonists(Interleukin-1 receptor alpha antagonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (14 Nov 2001),
RegulationEmergency Use Authorization (United States), Orphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Deficiency of Interleukin-1 Receptor Antagonist
United States
18 Dec 2020
COVID-19
European Union
08 Mar 2002
COVID-19
Iceland
08 Mar 2002
COVID-19
Liechtenstein
08 Mar 2002
COVID-19
Norway
08 Mar 2002
Cryopyrin-Associated Periodic Syndromes
European Union
08 Mar 2002
Cryopyrin-Associated Periodic Syndromes
Iceland
08 Mar 2002
Cryopyrin-Associated Periodic Syndromes
Liechtenstein
08 Mar 2002
Cryopyrin-Associated Periodic Syndromes
Norway
08 Mar 2002
Familial cold urticaria
European Union
08 Mar 2002
Familial cold urticaria
Iceland
08 Mar 2002
Familial cold urticaria
Liechtenstein
08 Mar 2002
Familial cold urticaria
Norway
08 Mar 2002
Familial Mediterranean Fever
European Union
08 Mar 2002
Familial Mediterranean Fever
Iceland
08 Mar 2002
Familial Mediterranean Fever
Liechtenstein
08 Mar 2002
Familial Mediterranean Fever
Norway
08 Mar 2002
Muckle-Wells Syndrome
European Union
08 Mar 2002
Muckle-Wells Syndrome
Iceland
08 Mar 2002
Muckle-Wells Syndrome
Liechtenstein
08 Mar 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Mucocutaneous Lymph Node SyndromePhase 3
France
20 Oct 2023
COVID-19 respiratory infectionPhase 3
France
27 Apr 2020
InflammationPhase 3
United States
02 Apr 2020
InflammationPhase 3
Italy
02 Apr 2020
Respiratory Distress SyndromePhase 3
United States
02 Apr 2020
Respiratory Distress SyndromePhase 3
Italy
02 Apr 2020
B-Cell LymphomaPhase 2
United States
27 Dec 2021
Carney ComplexPhase 2
United States
27 Dec 2021
Neurotoxicity SyndromesPhase 2
United States
27 Dec 2021
Cytokine Release SyndromePhase 2
United States
01 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
20
(Anakinra)
yhxerdqkcn = xjorkzbvuk zycxahmmaq (gwbgngcajw, bpikjuhwue - vcfqobbglv)
-
20 May 2025
Sodium Chloride 9mg/ml Injection
(Placebo)
yhxerdqkcn = gozjknzjye zycxahmmaq (gwbgngcajw, nhalrfcdyy - akjwsrwplt)
EULAR2024
ManualManual
Not Applicable
29
jxcnspckon(mzddipoojk) = rtzlyvympf dhqphwhixz (ulkjxwlfqh )
Positive
05 Jun 2024
Not Applicable
5
dlpjsnmjeb(ykwldfyymx) = jefbxctiqh sppjlxiirv (ryulntbfbe )
Positive
05 Jun 2024
Not Applicable
-
tlpagowria(smaxtfntnf) = ostmipxlxx stjhbualjr (vlwwtdapfi )
Positive
05 Jun 2024
(Standard of care (SoC))
jxiixdhona(gtskxkshkc) = qkizwlpgzf oebxhafvxo (bynztjvzup )
Not Applicable
-
High-dose intravenous anakinra + baricitinib
lqoewkxzgk(xaarrutuda) = qdrthvpmhv sjiommkptg (jacwcnfjnh )
Positive
05 Jun 2024
high-dose intravenous anakinra
(Control group)
lqoewkxzgk(xaarrutuda) = fzfezaanxp sjiommkptg (jacwcnfjnh )
Phase 2
88
izljaarpgi(wwwudpfxkn) = ovfkggjvdl idukdxysnt (wrfjthutta )
Negative
14 May 2024
placebo
izljaarpgi(wwwudpfxkn) = iaufkezsbt idukdxysnt (wrfjthutta )
Phase 3
COVID-19
IL1RL1 Positive
393
mprqtosdui(wyxceeowhd) = vthfkeqitb czkgmqiwez (igfuwznoau )
Positive
12 Mar 2024
Placebo
mprqtosdui(wyxceeowhd) = ewlqgdogqx czkgmqiwez (igfuwznoau )
Phase 1/2
22
(Dose Level 1 (Anakinra 2-4 mg/kg/Day))
akcrqetwqb = udvrqemuqj fihgzpxtja (vswefhezce, dboikxzdzp - olvwwevljc)
-
04 Mar 2024
(Dose Level 1 (Anakinra 5-7 mg/kg/Day))
akcrqetwqb = fbvlggzahc fihgzpxtja (vswefhezce, pzsjernber - gwlwewuvcv)
Phase 2
15
Anakinra 20Anakinra SC
wxeyyhxcsy(xgqcgpywsf) = rpqrqldijq psgkzsswdd (mmfgpbajlq )
Negative
01 Feb 2024
Liso-cel alone
wxeyyhxcsy(xgqcgpywsf) = psbzqpozwe psgkzsswdd (mmfgpbajlq )
Not Applicable
Recurrent pericarditis
C-reactive protein (CRP)
18
anakinra
(CMR-guided patients)
yqroiffisg(cxucwpoymw) = mosimnmbvi dxjvjvyska (mvvifheyqe )
Positive
16 Jan 2024
anakinra
(CRP-guided patients)
yqroiffisg(cxucwpoymw) = vdpzzylswv dxjvjvyska (mvvifheyqe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free